Laimang Biotech develops tumor immunotherapy drugs utilizing its proprietary Meta 10 immune metabolism reprogramming technology, which enhances T cell function through metabolic reprogramming and artificial intelligence. The company addresses the challenge of treating solid tumors by improving the efficacy and specificity of immune cell therapies while minimizing side effects.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors pose a significant challenge in cancer treatment due to the immunosuppressive tumor microenvironment and the limited efficacy of T cell therapies in penetrating and eradicating these tumors. Traditional approaches often struggle with T cell exhaustion and insufficient metabolic fitness, hindering their ability to effectively target and destroy cancer cells.
Solution
Laimang Biotech is developing tumor immunotherapy drugs using its proprietary Meta 10 technology, which enhances T cell function through immune metabolism reprogramming and artificial intelligence. The Meta 10 platform promotes metabolic reprogramming of terminally exhausted T cells, reactivating them and restoring their proliferative potential and killing activity. This approach aims to improve the efficacy and specificity of immune cell therapies while minimizing side effects in treating solid tumors. The company also utilizes AI algorithms to construct protein complex models, enhancing the response rate and specificity of Meta 10 while reducing toxic side effects.
Target Audience
The primary target audience includes patients with solid tumors who are not responding to conventional therapies, as well as pharmaceutical companies seeking to develop more effective cancer immunotherapies.
Features
- Meta 10 technology for metabolic reprogramming of T cells to enhance their anti-tumor activity
- AI-enabled platform for designing and optimizing ligands and receptors involved in T cell reactivation
- Development of metabolically enhanced CAR-T cell therapies for solid tumors
- Focus on improving T cell infiltration, persistence, and killing capacity within the tumor microenvironment
- Clinical trials evaluating the safety and efficacy of Meta10-enhanced CAR-T cells in various solid tumor types
- Technology licensed to other pharmaceutical companies to develop novel tumor immunotherapies